Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | UBE2N | P61088 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7518454 | 0.90 | ALDH1A1 (0.41) | MAOAMAOBL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL20863258 | 0.83 | KDM4E (0.43) | MAOAMAOBL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL7519245 | 0.83 | L3MBTL1 (0.42) | MAOAMAOBL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL1115532 | 0.82 | L3MBTL1 (0.41) | MAOAMAOBL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL7520223 | 0.82 | MAOB (0.40) | MAOAMAOBL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL3359066 | 0.82 | MAOA (0.42) | MAOAMAOBL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL7524643 | 0.81 | MAOA (0.40) | MAOAMAOBL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL7528193 | 0.80 | MAOB (0.40) | MAOAMAOBL3MBTL1KDM4EALDH1A1 | |
| Amotosalen SCHEMBL599618 | 0.79 | MAOA (0.44) | MAOAMAOBL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL1115728 | 0.79 | L3MBTL1 (0.44) | MAOAMAOBL3MBTL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0773716-A4 | TREATING RED BLOOD CELL SOLUTIONS WITH ANTI-VIRAL AGENTS | CERUS CORP (US) | 1999-08-04 | — | — | EP | claimed |
| EP-0773716-A1 | TREATING RED BLOOD CELL SOLUTIONS WITH ANTI-VIRAL AGENTS | Cerus Corporation (US) | 1997-05-21 | — | — | EP | claimed |
| WO-1996039818-A1 | TREATING RED BLOOD CELL SOLUTIONS WITH ANTI-VIRAL AGENTS | CERUS CORPORATION (US) | 1996-12-19 | — | — | WO | claimed |
| US-20020182581-A1 | Treating blood or blood products with compounds which have a mustard, aziridinium or aziridine group and a nucleic acid binding group | CERUS CORPORATION (US) | 2002-12-05 | — | — | US | disclosed |
| US-6410219-B1 | DECTIONN OF PATHOGEN DEACTION OF PATHOGEN BY COMPLEXING | CERUS CORPORATION | 2002-06-25 | — | — | US | disclosed |
| US-6171777-B1 | DECONTAMINATING BY CONTACTING WITH COMPOUND, THEN RECOVERING PRODUCT; DEACTIVATES HUMAN IMMUNODEFICIENCY AND HEPATITIS VIRUSES; BEFORE TRANSFUSIONS OR CLINICAL TESTS | CERUS CORPORATION | 2001-01-09 | — | — | US | disclosed |
| US-6143490-A | IN VITRO METHOD FOR DEACTIVATION OF VIRAL, BACTERIAL, OR PROTOZOAN PATHOGEN BY ADDING COMPOUND CONSISTING OF INTERCALATOR NUCLEIC ACID BINDING LIGAND AND AN ATTACHED MUSTARD GROUP, TREATING THE MIXTURE, AND RECOVERING BLOOD | CERUS CORPORATION (US) | 2000-11-07 | — | — | US | disclosed |
| EP-0773716-A4 | TREATING RED BLOOD CELL SOLUTIONS WITH ANTI-VIRAL AGENTS | CERUS CORP (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0773716-A1 | TREATING RED BLOOD CELL SOLUTIONS WITH ANTI-VIRAL AGENTS | Cerus Corporation (US) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996039818-A1 | TREATING RED BLOOD CELL SOLUTIONS WITH ANTI-VIRAL AGENTS | CERUS CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020182581-A1 | Treating blood or blood products with compounds which have a mustard, aziridinium or aziridine group and a nucleic acid binding group | ADAR, CD99, AAAS | MAOA 3813/4885MAOB 2679/4885L3MBTL1 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.